protocol IntroDuctIon
Pyrogenic (pyros is Greek for fire) contaminations pose a major safety concern for patients because their introduction into the human body, e.g., via parenterals, cell therapies or medical devices may cause severe reactions ranging from fever to shock and death. Known pyrogens are of microbial origin, but their presence does not correlate with colony-forming units, i.e., number of viable microorganisms, or with the presence of microbial genetic material. Examples of known pyrogens include lipopolysaccharides (LPS), i.e., well-described, highly potent endotoxins of Gram-negative bacteria; lipoteichoic acid (LTA) 1 , lipopeptides and peptidoglycan 2 from Gram-positive bacteria; exotoxins 3 ; enterotoxins 4, 5 ; viruses 6 ; and fungal components 7, 8 .
Development of the protocol
In mammals the exposition of inner tissues to pyrogens leads to the secretion of the so-called endogenous pyrogens by immune cells, i.e., blood monocytes and tissue macrophages 9 , which when injected into mammals induce fever reactions. The most potent endogenous pyrogen is the proinflammatory cytokine interleukin (IL)-1β (refs. 10,11) , which binds to receptors on the blood side of the organum vasculosum laminae terminalis, one of the circumventricular organs of the brain, and initiates the expression of the enzyme cyclooxygenase-2 (COX-2) 12, 13 , which converts arachidonic acid to prostaglandin (PG)E 2 . PGE 2 then mediates an increase in temperature 14 . Mice deficient in COX-2 do not develop fever in response to injection of IL-1β or LPS [15] [16] [17] . Our basic idea that led to the development of the in vitro pyrogen test (IPT) was to use human immune cells to detect exogenous pyrogens by measuring the release of an endogenous pyrogen 18 . Diluted fresh or cryopreserved blood is incubated for 10-24 h at 37 °C with the test samples, spiked test samples, endotoxin controls and negative controls. The blood monocytes produce proinflammatory cytokines in response to any pyrogen present in a concentration-dependent manner and the IL-1β produced is measured by enzyme-linked immunosorbent assay (ELISA).
Human whole blood containing monocytes was chosen as an accessible source of primary human immune cells. The advantage of using whole blood instead of isolated cells, such as blood monocytes, is that all the immune cell types and serum components are present in their natural composition, and sources of contamination or preactivation of the cells are reduced as no isolation procedures are required.
Interleukin-1β was chosen as a readout parameter as it is consistently released in a concentration-dependent manner by blood from different donors 19 upon exposure to the same minimal pyrogenic stimulation and can be readily measured by an ELISA. The sandwich ELISA is a highly specific and sensitive immunological assay that can detect antigens in the low pg ml − 1 range. The use of two antibodies, usually one monoclonal and one polyclonal antibody preparation, ensures high specificity, while linking the secondary antibody, directly or via biotin-streptavidin binding, to the enzyme horseradish peroxidase that metabolizes tetramethylbenzidine (TMB) ensures a high level of sensitivity.
The IPT thus poses a physiologically relevant human test system for the assessment of pyrogenic contaminations. It has successfully undergone an international validation process 20, 21 for both fresh and cryopreserved blood, and will be included in the European Pharmacopoeia in 2010 as announced by the European Directorate for the Quality of Medicines & Health Care (www.edqm.eu/medias/ fichiers/133rd_Session_of_the_Eu.pdf). A similar statement by the United States Food and Drug Administration is pending. The IPT test will help to significantly reduce the use of animals for research and safety assessments in cosmetic and pharmaceutical industry. The methodology of IPT using either fresh or cryopreserved blood as well as its adaptations described herein are protected for commercial use by international patents [22] [23] [24] .
Applications of the method
We have adapted the basic protocol of IPT, originally developed for the detection of pyrogens in aqueous liquid samples such as parenteral medications using fresh human whole blood, to a variety of different specific requirements. These adaptations include the development of cryopreserved human whole blood as an alternative to fresh human whole blood 25 , the assessment of the pyrogenicity 26, 27 , and the evaluation of airborne pyrogenic burden 28 , all of which are detailed herein. The assay opens up new avenues for the control of cell therapies (from blood infusions to stem cells), medical devices and topical applications of substances with specific concerns (intrathecal injections, eye drops and baby food). It allows the assessment of laboratory reagents (e.g., recombinant proteins) and equipment (e.g., cell culture materials) for pyrogenic contaminations.
Other applications for more specialized requirements are described elsewhere. They include a specific protocol for testing lipidic substances and lipid-enclosed drugs that may interfere with pyrogen detection 29 . Some drugs may be cytotoxic or immunomodulatory and thus interfere with the whole-blood test independent of their containing possible pyrogenic contaminations. We have overcome this problem by collecting pyrogens from such samples onto bead-immobilized human serum albumin (HSA-beads) 30, 31 . This allows the separation of pyrogens from the interfering drug by washing the beads and subjecting them to IPT. Similarly, the HSA-beads allow the accumulation of pyrogens from water samples or samples of dialysis fluids, where even very low-grade concentrations of pyrogens may be relevant, as for example a dialysis patient is exposed to many liters of dialysis fluids per session.
Comparison with other methods
Until now, pyrogenic contamination of parenterals has been assessed by animal testing, i.e., the rabbit pyrogen test 32, 33 , or by employing the limulus amoebocyte lysate (LAL) test. Both tests carry essential limitations: in the rabbit test, next to ethical concerns, animal handling easily gives false-positive or negative results 34 , humans differ in their sensitivity to pyrogens from rabbits, and rabbits cannot be employed to test a range of modern pharmaceutical products, especially biologicals, cancer drugs and immunomodulatory drugs, owing to interference effects 35 . It should be noted that the rabbit assay, which was adopted in 1940, has never been formally validated, and no conclusive data for the detection of pyrogens other than LPS are available. The LAL, which employs the blood of horseshoe crab Limulus polyphemus, drawn from living crabs, detects only LPS and does not reflect the different potencies of LPS from different bacterial species observed in humans 36, 37 . It also gives false-positive reactions in the presence of glucans and a number of herbal preparations 35 .
Further in vitro pyrogen tests using other cell populations, i.e., peripheral blood mononuclear cells or the cell line Monomac6 were internationally validated in parallel with the test described here 20, 21, 38 . In contrast to these, the whole-blood assay requires no cell preparation procedures that are more time consuming and are prone to preactivation of cells, and no cell culture, which requires special facilities and is available as a ready-to-use, qualitycontrolled kit, thereby minimizing the time to set up and validate the assay.
Experimental design Sample types. Sterile, pyrogen-free materials must be used for all steps excluding the ELISA procedure. It is recommended that the whole-blood incubation steps be carried out under a laminar flow bench to avoid contaminations. An overview of the different protocol options developed for specific applications and to suit users' requirements is given in Figure 1 . The type of sample, whether liquid, solid or air determines the whole-blood incubation format. With regard to liquid samples and some solid samples, depending on their dimensions, the whole-blood incubation may be carried out in 1.5 ml reaction vials or in microtiter plates. Microtiter plates are recommended where the sample volume is limiting, however, they must be placed in an incubator. In contrast, 1.5 ml reaction vials can alternatively be inserted into a thermoblock if an incubator is not accessible. For solid samples that are too large for plates or vials, a pyrogen-free incubation vessel must be identified in which the sample can be completely submerged for whole-blood incubation, e.g., 50 ml falcons or depyrogenized glassware or metal vessels may be suitable. Glassware can be depyrogenized by incubation with 0.5 M NaOH for 30 min, followed by extensive washing with purified water (e.g., Milli-Q); the pyrogenic activity of water should be tested before use. Alternatively, heat-stable glassware or metal vessels may be covered with aluminum foil and submitted to dry sterilization at 250 °C for 3 h, followed by extensive washing with purified water (e.g., Milli-Q). Determination of the pyrogenic burden in air requires the collection of airborne particles on a pyrogen-free, biocompatible membrane to allow interaction of the blood with the particles (see Box 1 for details). A resealable air monitor cassette containing a polytetrafluoroethylene (PTFE) membrane with a pore diameter of 5 µm has proven useful for this. Sealed air monitor cassettes may be stored dry at 4 °C for up to 7 d after sampling.
Aqueous liquid samples may need to be employed in different dilutions (e.g., a 1:10 dilution series) to exclude interference (see below) or to allow a semi-quantitative readout (see below). A semi-quantitative assessment of the pyrogenic burden of solid samples is only possible if the sample can be employed in different quantities, e.g., fibers and beads. Otherwise only a rough estimation is possible (see below). For the assessment of pyrogenic activity in air samples, it is recommended to pump a broad range of air volumes through different air monitor cassettes (e.g., 1, 3, 10, 30, 100 and 300 liters) to allow a semi-quantitative assessment (see below) of the pyrogenic burden.
Use of fresh blood or cryopreserved blood. Fresh human whole blood should be obtained from a healthy and nonallergic donor who has not taken any medication for at least 14 d. The blood is drawn by venipuncture into sterile, heparinized vials. Blood may only be drawn by a trained physician or nurse in accordance protocol with the legal requirements of the country and guidelines of the institution. Determination of a normal white blood cell count, e.g., by blood smear and microscopic evaluation or by using either an electronic cell counter or image analysis instrument, is recommended to exclude acute infection. The blood must be used for incubation within 4 h of being drawn, as the sensitivity of the blood to pyrogens decreases after this time. During this time it may be stored at room temperature (15 -30 °C) .
The choice between fresh blood and cryopreserved blood is determined by a laboratory's accessibility to fresh human blood within 4 h of starting the whole-blood incubation step and the possibility to store cryopreserved blood at − 70 °C or in liquid nitrogen. Cryopreserved blood can be produced 25 or obtained in large lots from a pool of donations by different healthy donors, and the batch can be pretested for HIV or Hepatitis B antibodies as an added safety precaution. Cryopreserved blood must be incubated in a 5% CO 2 atmosphere to ensure cytokine release on pyrogenic stimulation.
The total volume of blood required is determined by the number of samples and controls, and the volume of incubations, e.g., 20 µl per well for microtiter plates, 100 µl per reaction vial or 300 µl per air monitor cassette for airborne samples. Fresh blood is diluted in clinical-grade saline (150 mM) to a final dilution of 1:12. Cryopreserved blood is already diluted 1:2 by the cryopreservation procedure and is further diluted 1:6 in RPMI 1640 to a final dilution of 1:12. The dilution with RPMI 1640 must occur immediately after thawing for 15 min at 37 °C to avoid toxic effects of the cryopreservative DMSO. The dilution of 1:12 results in a high release of cytokines using a minimal amount of blood. A recent report demonstrated that the cytokine inhibitor α-1-antitrypsin is no longer active at this dilution, which explains why the cytokine release is higher and thus more robustly detectable in diluted samples 39 .
Detection of IL-1 release. The levels of IL-1β released in the course of the whole-blood incubation are determined by ELISA. For diagnostic, clinical or commercial purposes the qualityassured IPT kit, which contains all reagents required for the wholeblood incubation apart from the blood itself, is recommended. For research purposes, the cheaper option of an IL-1β ELISA kit or respective antibody pairs may be chosen instead. An IL-1β ELISA kit generally contains all ELISA components including the antibodies, recombinant IL-1β standard (not required for IPT), microtiter plate, buffers and other reagents as well as a detailed protocol, which also gives the sensitivity and specificity of the assay. Antibody pairs are pretested for compatibility in the respective ELISA, and a recommendation for the concentration to be used is usually given in the data sheet by the manufacturer. The other ELISA components can be bought in bulk, and the buffers can be mixed using standard laboratory chemicals. The ELISA must then be set up, optimized and validated. The sensitivity is determined using recombinant IL-1β cytokine and must reach down to the low pg ml − 1 range to allow IPT testing. Setting up an ELISA in this way requires some experience in immunological techniques but reduces the cost per ELISA substantially in comparison with the IPT kit or the ELISA kit if the assay is carried out regularly. New batches of components must always be validated against the former batches to ensure consistency of results.
The ELISA plate is coated with the primary antibody. The IL-1β in the sample is then sandwiched between the primary coat antibody and a secondary horseradish peroxidase-labeled detection antibody or a biotinylated detection antibody. In the latter case, a streptavidin-linked horseradish peroxidase is added after washing. The unbound material is removed by washing. The peroxidase metabolizes the substrate 3,3′,5,5′-TMB. The reaction is stopped with hydrochloric or sulfuric acid, and the optical density (OD) is measured at 450 nm against a reference wavelength of 600 to 690 nm. No IL-1β reference material is required to quantify IL-1β protein as the ELISA OD readout is compared with that of the endotoxin controls. It is to be noted that various other cytokines (e.g., IL-6, TNF and IL-8) and PGE 2 and assays on protein or mRNA level have been shown to give similar results as the IL-1β ELISA but require in-case validation against the standard protocol 18 .
Design of an incubation plan. The design of an incubation plan is essential before the initiation of the experiment. Each incubation setup should be composed of endotoxin controls (0.5 EU ml − 1 is necessary for qualitative assessment; a range of endotoxin controls, e.g., 0.25, 0.5, 1.0, 2.5 and 5.0 EU ml − 1 is required for semi-quantitative assessment), a negative control (saline for fresh blood or RPMI 1640 for cryopreserved blood), samples and respective spiked samples (spiked with 0.5 EU ml − 1 of the endotoxin control). Spiked samples are only required for interference testing in new samples. Data should be collected in quadruplicate. Ideally, the incubation plan should already correspond to the given requirements of the respective ELISA reader software to allow easy transfer of samples after the whole-blood assay onto the ELISA plates. Table 1 presents a recommended incubation plan. The number of samples and spiked samples will vary depending on the experiment. 40) or another LPS that has been calibrated against this WHO reference standard by LAL assay, e.g., control standard endotoxin (CSE) or the LPS from E. coli O111:B4 included in the IPT kit. As LPS from different species may differ in potency and preparations from the same species may vary in potency between batches, the calibration against the WHO standard ensures that the same stimulus potency is used in every assay, thus ensuring comparability of results. One concentration of the endotoxin controls, i.e., 0.5 EU ml − 1 , is also employed to prepare spiked samples for an interference test, which is required for any new sample types or drug formulations (see below). The spike is allowed to interact with the sample for 2 h at room temperature, i.e., 15-30 °C before incubation with human whole blood.
Box 1 | MeAsureMent of AirBorne pyrogens
Statistical analysis. All samples are assayed in quadruplicates. This allows outlier analysis using the methods described by Dixon or Grubbs 41, 42 .
Validity of the assay. Two criteria must be fulfilled for the assay to be valid. First, the mean OD of the negative controls must lie at or below 100 mean OD. Second, the mean OD of 0.5 EU ml − 1 control must be greater than 1.6 times the mean OD of the negative controls. The endotoxin control at a concentration of 0.5 EU ml − 1 corresponds to 50 pg ml − 1 of the WHO international reference standard from E. coli O113:H10 and is the threshold endotoxin concentration that causes fever in 50% of animals of the most sensitive rabbit strains. This threshold was confirmed by a study carried out at the Paul-Ehrlich Institute in 2005, which analyzed 171 rabbits 43 .
Interference test. To exclude putative interferences of test substances with the activity of blood cells, e.g., toxicity or immunomodulation, new sample types or drug formulations should be spiked with an endotoxin control (0.5 EU ml − 1 ) in parallel to the incubation with the unspiked sample. The mean OD of the spiked sample replicates must lie within a 50-200% range of the 0.5 EU ml − 1 concentration of the endotoxin control. If this is not the case, then the sample is interfering with the assay and the experiment must be repeated using a diluted sample and spiked once again until the interference is excluded. However, the maximum valid dilution (MVD) or minimal valid concentration (MVC) may not be overstepped. These are calculated figures that indicate the degree to which a product may be diluted to overcome interference before the effect of dilution exceeds the ability of the test method to detect pyrogens in the original preparation. The MVD is usually applied to preparations already in liquid form, wherein the dose is administered per ml and the endotoxin limit is expressed as EU ml − 1 . The MVC is applied to those preparations wherein the endotoxin limit is expressed as EU mg − 1 and the dose is expressed as mg kg − 1 body weight. If interference cannot be excluded before MVD or MVC is reached, other assay variants may be helpful 30, 31 . Interference must only be excluded for each new sample, i.e., it does not have to be repeated for every batch of similar preparation.
Estimation of the sample pyrogenic activity. Samples that induce the release of values of IL-1β higher than the positive control sample containing 0.5 EU ml − 1 are considered positive for pyrogenic contamination (qualitative assessment). The IPT also detects the activity of pyrogens other than LPS, e.g., LTA, exotoxins and fungal components, without identifying the pyrogen type or pyrogen mixture composition. The concentration response curves of different pyrogens do not necessarily run in parallel. Therefore, the readout of IPT is generally qualitative, i.e., the sample is positive or negative in comparison with 0.5 EU ml − 1 endotoxin control. For a semi-quantitative assessment of the pyrogenic activity using liquid samples, a limit dilution may be carried out, i.e., samples are employed in different dilutions (e.g., a series of 1:10 dilutions) and the dilution that results in IL-1β release that is comparable with 0.5 EU ml − 1 endotoxin control is used to calculate the endotoxin contamination in the undiluted sample. This estimation is given in endotoxin-equivalent units (EEUs) in consideration of the fact that non-LPS pyrogens may be contributing to the pyrogenic activity. Similarly, a semi-quantitative assessment of the pyrogenic burden in air samples may be given in EEU by comparison of the IL-1β induction in the monitors sampled with different volumes of air. Again, the sample inducing IL-1β release comparable with 0.5 EU ml − 1 endotoxin control should be used to calculate the total EEU in the Timing. It is most efficient to set up the whole-blood incubation during one working day, leave it to incubate overnight and carry out the ELISA on the following day. Although some ELISA kits contain plates already coated with the primary antibody, other kits as well as ELISA's setup with antibody pairs will require the primary antibody to first be coated to the ELISA plate. This may be set up on the first day, leaving the coating process to occur overnight at 4 °C parallel to the whole blood incubation.
MaterIals

REAGENTS IPT using fresh human whole blood
Human whole blood from healthy volunteers (stored for up to 4 h at room temperature) ! cautIon Human blood may transmit infectious diseases such as Hepatitis B or HIV. Use protective gloves, dispose of contaminated sharp waste in safety containers at the point of use, dispose of contaminated waste after autoclaving. ! cautIon Experiments with human subjects must comply with institutional and national guidelines.
IPT using cryopreserved human whole blood
Cryopreserved blood prepared according to 21 or obtained from commercial sources, e.g., Qualis Laboratorium GmbH. Blood may be stored at − 70 °C or in liquid nitrogen for at least 6 months ! cautIon Human blood may transmit infectious diseases such as Hepatitis B or HIV. Use protective gloves, dispose of the contaminated sharp waste in safety containers at the point of use, dispose of contaminated waste after autoclaving. Pyrogen-free RPMI 1640 (included in the IPT kit) (e.g., BioWhittaker Europe, Lonza, cat. no. BE12-702G/U1 ) (e.g., GSM, cat. no. SG400ex) REAGENT SETUP Endotoxin control Prepare a 2,000 EU ml − 1 stock solution using clinical grade saline. Aliquots (e.g., 50 µl) can be stored at − 20 °C for up to 6 months. Vortex stock solutions and all dilutions made from these for at least 60 s directly before use. Coating buffer Prepare a solution of 0.1 M NaHCO 3 in deionized water; can be stored at − 20 °C for 6 months. Blocking and dilution buffer Prepare a solution of 14 mM NaCl, 1.5 mM KH 2 PO 4 , 6.5 mM Na 2 HPO 4 , 2.7 mM KCl in deionized water; adjust the pH to 7.0. Add 30 g l −1 bovine serum albumin and stir until dissolved. Can be stored at − 20 °C for 6 months.  crItIcal Add bovine serum albumin after pH adjustment. Washing buffer Prepare a solution of 14 mM NaCl, 1.5 mM KH 2 PO 4 , 6.5 mM Na 2 HPO 4 , 2.7 mM KCl in deionized water; adjust the pH to 7.0. Add 0.05% Tween 20 (vol/vol). Can be stored at 4 °C for 1 week.  crItIcal Add Tween20 after pH adjustment. Whole-blood incubation • tIMInG 13-27 h 4| Pyrogenic activity can be measured using option A fresh human whole blood or option B cryopreserved human whole blood. ! cautIon All experiments using human blood must comply with the legal requirements of the country and guidelines of the institution. Human blood may transmit infectious diseases such as Hepatitis B or HIV. Use protective gloves, dispose of contaminated sharp waste in safety containers at the point of use, dispose of contaminated waste after autoclaving.
(a) Fresh human whole blood (i) Determine the final volume of the assay by e.g., considering for liquid samples whether vials or a microtiter plate is being used (in which case, the final volume should be 1,200 µl and 240 µl, respectively) or whether solid samples are being used (in which case, the final volume should be adapted according to the requirements) (see table 2 Step viii.  crItIcal step Use the thawed cryopreserved blood within 15 min to prevent the high concentration of DMSO from becoming toxic to the cells. (viii) Resuspend the blood by gently inverting the closed vials. Combine blood from different vials into one pyrogen-free reservoir. Add two parts of cryopreserved human whole blood to each receptacle to reach the total incubation volume.
5|
For samples assayed in vials mix the samples by closing the reaction vials and gently inverting the tubes a few times. For samples prepared in microtiter plates, mix by aspiring and dispensing five times. Change tips between each sample to avoid cross contamination. Cover the microtiter plate with a lid. For solid samples, mix the contents by gently inverting the receptacles by swinging them manually.
6|
Incubate samples prepared with fresh blood in an incubator or a heating block for 10-24 h at 37 °C ± 1 °C. Incubate samples prepared with cryopreserved blood in an incubator for 10-24 h at 37 °C ± 1 °C and 5% CO 2 . 7| Mix the samples as described in Step 5. Aliquot the contents (≥300 µl) of the receptacles that contained solid samples into 1.5 ml tubes. Samples in tubes can be used directly or be centrifuged for 2 min at 10,000g, room temperature and the cleared supernatant is collected. Samples can be used immediately for ELISA analysis or stored for later use or to repeat the assay. For storage, aliquot samples into microtiter plates and seal with a lid or plastic tape.  pause poInt Sealed plates may be frozen at − 20 °C for no longer than 4 weeks or at − 70 °C until required.
Determining Il-1 content in samples by elIsa • tIMInG 20 h 8| Coat a Multisorp ELISA plate with 50 µl of primary antibody solution (e.g., MAB601 at 250 ng ml 
11|
Add 50 µl of secondary antibody per well (e.g., BAF201 at 60 ng ml − 1 ) diluted in blocking solution and add 50 µl of samples per well from whole-blood incubation (Step 4 A) or 50 µl of samples per well from the cryopreserved blood incubation (Step 4B). Incubate at room temperature for 2 h.  crItIcal step Change pipette tips to avoid cross contamination.
12| Wash all the wells four times with 250 µl washing buffer per well. antIcIpateD results Figure 2 shows an ELISA plate of an IPT carried out with fresh human whole-blood incubated for 20 h after stopping the TMB metabolism with sulfuric acid according to the incubation plan given in table 1.
13|
The minimum assay suitability requirements are as follows: • The mean OD of control samples is 0.1 OD or below.
• The ratio of mean OD of 0.5 EU ml − 1 endotoxin control over the mean OD of control samples is greater than 1.6. • Interference of the samples is excluded. If an unspiked sample is nonpyrogenic, i.e., the OD lies below the mean OD of 0.5 EU endotoxin control, and the mean OD of the respective spiked sample lies within a 50-200% range of the mean OD (0.5 EU ml − 1 ), this sample is free of interference. If the minimum assay suitability requirements are fulfilled, the prediction model can be applied: Rabbits are likely to develop fever if tested with 10 ml kg − 1 of the sample if: mean OD (sample) > mean OD (0.5 EU ml − 1 ). This is a qualitative evaluation for which the IPT has been validated, the readout being either "pyrogenic" or "nonpyrogenic". For a semi-quantitative assessment of the pyrogenic activity in liquid samples, the dilution which results in an OD that is comparable to 0.5 EU ml − 1 endotoxin control can be used to calculate the endotoxin contamination in the undiluted sample. This estimation should be given in EEU because non-LPS pyrogens may also contribute to the pyrogenic activity. Similarly, the pyrogenic burden in air samples may be given in EEU by comparison of the IL-1β induction in the air monitor cassettes with that of 0.5 EU ml − 1 control. For solid samples a similar semi-quantitative assessment is possible if the samples can be employed in different quantities, e.g., fibers and beads. Otherwise only a rough estimation can be made by finding comparable IL-1β An example for the detection of pyrogenic activity in a liquid sample is given in Figure 3a. Here a cooling lubricant was tested for pyrogenic activity. Samples were employed at different dilutions and spiked with 0.5 EU ml − 1 LPS at each of these dilutions. Horizontal lines show the OD value of the endotoxin control (0.5 EU ml − 1 ) and the range of 50-200% of this value. At dilutions below 1:100 interference is observed, as the spiked sample does not reach an OD greater than 50% of the endotoxin control. At dilutions starting from 1:100 the OD of the spiked sample is within this range and interference is excluded. A vitality test (AlamarBlue metabolism) carried out with the diluted blood after the whole-blood incubation (Fig. 3b) demonstrated that the interference at dilutions below 1:100 was caused by toxic effects to the blood cells. Figure 4 shows an example of assessment of the pyrogenic burden in air samples from different environments. As would be expected, the pyrogenic burden in a hog house was far greater than that in an office environment.
In Figure 5 surgical steel beads were tested as an example of solid samples used in the IPT. The spiked sample results in an OD in the 50-200% range of the 0.5 EU ml − 1 endotoxin control, thus interference is excluded. The samples were negative for pyrogenic activity.
Different donors release different absolute amounts of IL-1β in response to pyrogenic stimulation. However, their sensitivity to pyrogens is highly comparable 19 . This is the reason why the endotoxin controls must always be run in parallel with the Pyrogenic activity of particles from air sampled using air monitor cassettes was evaluated by IPT. Various volumes of air were sampled at different locations. The whole-blood incubation was carried out in air monitor cassettes with negative controls, endotoxin controls () (given in EU ml − 1 ) and samples. After 20 h incubation with whole blood the IL-1β ELISA was carried out and the absorbance at 450 nm recorded. Error bars are the s.d. of quadruplicate samples. All experiments using human blood must comply with the legal requirements of the country and guidelines of the institution. protocol sample assessment. Similarly, although the cryopreserved blood generally results in a somewhat higher absolute release of IL-1β, the sensitivity of fresh blood and cryopreserved blood to pyrogens is highly comparable, see e.g., Figure 6. acknoWleDGMents The authors acknowledge the contributions of countless scientists, technicians, students, authorities and funding institutions to the development and validation of these protocols.
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